Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07734012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

Study acronym: IMPACT-SSc
StatusNot Yet Recruiting
PhasePhase 2
Started2026-08
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 3 → 4 primary endpoints
See other at-risk trials from Ottawa Hospital Research Institute

Amendment history

2026-08-05
Study Status, Arms and Interventions, Outcome Measures v1
Primary endpoint(s) modified3 to 4 entries
WasEfficacy :, Feasibility:, Safety : AEs/SAEs
NowEfficacy :, Efficacy:, Feasibility:, Safety : AEs/SAEs
Secondary endpoints6 to 8 entries
Clinical outcome: Clinical outcome:
2026-07-24
Original filing
A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible . We are studying whether a brief course of treatment with MMF after AHSCT will serve to prevent disease relapse.
Trial Details
NCT Number NCT07734012
Lead Sponsor Ottawa Hospital Research Institute
Collaborators: The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant.
Conditions Systemic Sclerosis (SSc)
Enrollment 6 participants
Start Date 2026-08
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07